Receptor-Targeted Photodynamic Therapy of Glucagon-Like Peptide 1 Receptor–Positive Lesions
Open Access
- 8 May 2020
- journal article
- research article
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 61 (11) , 1588-1593
Abstract
Treatment of hyperinsulinemic hypoglycemia is challenging. Surgical treatment of insulinomas and focal lesions in congenital hyperinsulinism (CHI) is invasive and carries major risks of morbidity. Medication to treat nesidioblastosis and diffuse CHI has varying efficacy and causes significant side effects. Here, we describe a novel method for therapy of hyperinsulinemic hyperglycemia, highly selectively killing beta cells by targeted photodynamic therapy (tPDT) with exendin-4-IRDye700DX, targeting the glucagon-like peptide 1 receptor (GLP-1R). A competitive binding assay was performed using Chinese hamster lung (CHL) cells transfected with the GLP-1R. The efficacy and specificity of tPDT with exendin-4-IRDye700DX was examined in vitro in cells with different levels of GLP-1R expression. Tracer biodistribution was determined in BALB/c nude mice bearing subcutaneous CHL-GLP-1R xenografts. Induction of cellular damage and the effect on tumor growth were analyzed to determine treatment efficacy. Exendin-4-IRDye700DX has a high affinity for the GLP-1R with an IC50 value of 6.3 nM. TPDT caused significant specific phototoxicity in GLP-1R positive cells (2.3 ± 0.8 % and 2.7 ± 0.3 % remaining cell viability in CHL-GLP-1R and INS-1 cells resp.). The tracer accumulates dose-dependently in GLP-1R positive tumors. In vivo tPDT induces cellular damage in tumors, shown by strong expression of cleaved-caspase-3 and leads to a prolonged median survival of the mice (36.5 vs. 22.5 days resp. p<0.05). These data show in vitro as well as in vivo evidence for the potency of tPDT using exendin-4-IRDye700DX. This could in the future provide a new, minimally invasive and highly specific treatment method for hyperinsulinemic hypoglycemia.Keywords
This publication has 32 references indexed in Scilit:
- Radiolabelled GLP‐1 analogues forin vivotargeting of insulinomasContrast Media & Molecular Imaging, 2012
- Hyperinsulinaemic hypoglycaemia: genetic mechanisms, diagnosis and managementJournal of Inherited Metabolic Disease, 2012
- Cancer cell–selective in vivo near infrared photoimmunotherapy targeting specific membrane moleculesNature Medicine, 2011
- Glucagon-like Peptide 1–Receptor Scans to Localize Occult InsulinomasNew England Journal of Medicine, 2008
- Vascular‐targeted photodynamic therapy (padoporfin, WST09) for recurrent prostate cancer after failure of external beam radiotherapy: a study of escalating light dosesBJU International, 2008
- Is Laparoscopic Resection Adequate in Patients with Neuroendocrine Pancreatic Tumors?World Journal of Surgery, 2008
- Current Clinical and Preclinical Photosensitizers for Use in Photodynamic TherapyJournal of Medicinal Chemistry, 2004
- Photodynamic therapy for cancerNature Reviews Cancer, 2003
- Photodynamic therapy for cancer of the pancreasGut, 2002
- Signal transduction of the GLP‐1‐receptor cloned from a human insulinomaFEBS Letters, 1994